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Patients with advanced gastric cancer have a poor prognosis. 5-Fluorouracil (F) and cisplatin (C) based regimens are often
considered to be reference regimens in the treatment of patients with advanced gastric cancer. Best supportive care in advanced
gastric carcinoma results in median survival times of 3–4 months. Docetaxel (D) plus cisplatin and 5-ﬂuorouracil was selected
by an Independent Data Monitoring Committee as the test regimen for the second (phase III) stage of the V325 study on the
basis of the response rate in the randomised phase II ﬁrst stage. Chemotherapy–na€ıve patients were randomised to receive
either DCF or CF. Tumour assessments were independently reviewed. At a planned interim analysis on 223 patients (111
DCF/112 CF) both the median time to progression and overall response rate were statistically superior in the DCF arm (5.2
months versus 3.7 months, and 39% versus 23%, respectively). The increase in median survival, 10.2 months compared with 8.5
months in this interim analysis did not yet reach statistical signiﬁcance. The results of the full study population are awaited
eagerly.
 2004 Elsevier Ltd. All rights reserved.
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Gastric cancer is a debilitating, aggressive disease that
is frequently not diagnosed until it has reached an ad-
vanced stage and is a major health problem in many
parts of the world. Patients with metastatic disease have
a poor prognosis [1]. The median survival of patients
with advanced gastric cancer is low. In several rando-
mised trials of Best Supportive Care (BSC) versus che-
motherapy, BSC care results in median survival times of
only 3–4 months versus 7–9 months for chemotherapy.
In two trials it was shown that the quality of life of
patients treated with chemotherapy was better than the
quality of life of patients treated with BSC [2,3].
Currently, no single agent or combination regimen
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C, doxorubicin and 5-ﬂuorouracil (5-FU) (FAM regi-
men), eﬀected only a short-lived response in a small
proportion of patients [4]. In the 1980s and 1990s, a
number of combination regimens, such as 5-FU com-
bined with cisplatin (FUP), doxorubicin and metho-
trexate (FAMTX regimen), etoposide and folinic acid
(ELF), and epirubicin plus cisplatin (ECF), or the
combination etoposide, doxorubicin and cisplatin
(EAP regimen) produced encouraging results [5–8].
However, the high response rates achieved in initial
studies were not always supported by subsequent more
extensive studies. Although gastric cancer is a relatively
chemosensitive cancer, the responses are often short-
lived and the complete response rate is very low.
Moreover toxicity is often important for these patients
who often have a poor performance status. In light of
the data from diﬀerent trials, 5-FU and cisplatin-based
regimens are considered as reference regimens. Al-
though the ECF regimen is probably the most widely
used and the best validated of these regimens, several
options are possible. These are the ECF regimen
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every 3 weeks in combination with 5-FU 200 mg/m2/
day), the FUP regimen (5-FU 1000 mg/day on days
1–5 in combination with cisplatin 100 mg/m2 day 1),
the weekly AIO regimen plus cisplatin (50 mg/m2 every
2 weeks) and LV5FU2 plus cisplatin (50 mg/m2 every 2
weeks). The preferred regimen is diﬀerent for diﬀerent
countries.
Among the newer cytotoxic agents with potential
activity in advanced gastric cancer, irinotecan and do-
cetaxel have been of considerable interest. Both have
been shown to be active alone [9–11] and in combination
with cisplatin [11–14] and 5-FU [15–18]. In the irino-
tecan studies, 5-FU was combined with folinic acid
(FA). In a recent randomised phase II study, the eﬃcacy
and toxicity proﬁle of a combination of irinotecan and
5-FU/FA were found to be favourable compared with
5-FU/FA alone [19]. A randomised phase III trial
comparing irinotecan plus 5-FU/FA with cisplatin plus
5-FU is currently in progress [20].
A review of the main clinical trials using docetaxel in
advanced gastric cancer has recently been published [11].
Eight phase II trials reported the use of docetaxel as a
single agent. In these studies, which included a total of
262 evaluable patients, the mean response rate was 19%
(95% CI 14–24%) and docetaxel was well tolerated, with
myelosuppression being the dose-limiting eﬀect. Ad-
ministration of docetaxel in combination with cisplatin
resulted in response rates of 56%, 37% and 36% in three
phase II trials, and with a response rate of 35% in one
phase III trial.
The relatively low haematological toxicity of 5-FU
when administered by continuous infusion, and its role
in the eﬃcacy of other 5-FU-based regimens, make it a
logical choice for addition to the combination of do-
cetaxel and cisplatin. Studies have shown that 5-FU can
be added to docetaxel/cisplatin without the need for
dose reduction of either of these two drugs [17,18].
Against this background, a multinational trial (V325)
was set up to evaluate the value of docetaxel in combi-
nation with cisplatin, with or without continuous infu-
sion 5-FU, in metastatic gastric carcinoma. The trial
comprised two stages. The ﬁrst stage was a randomised
phase II clinical trial comparing docetaxel/cisplatin with
docetaxel/cisplatin/continuous 5-FU (DCF), and was
intended to identify the test arm to be taken forward
into a phase III comparison with cisplatin/5-FU (CF).
An Independent Data and Safety Monitoring Commit-
tee (IDMC) was set up to make this decision according
to the response rate and safety reported with each reg-
imen. The DCF arm was associated with a higher re-
sponse rate than the docetaxel/cisplatin arm (43% versus
26%, respectively) [21,22] and was thus selected as the
regimen to be compared with CF in the randomised
phase III trial. The preliminary data from a planned
interim analysis of this trial are reported here [23,24].2. Patients and methods
This was a phase III, multicentre, randomised trial
comparing DCF with CF in patients with locally ad-
vanced or metastatic gastric adenocarcinoma.
2.1. Patient eligibility
Eligibility criteria were: histologically proven meta-
static or locally recurrent gastric adenocarcinoma (in-
cluding gastro-oesophageal adenocarcinoma); age >18
years with a Karnofsky performance status (KPS) of
>70%; no prior adjuvant chemotherapy (except where
12 months have elapsed between prior adjuvant che-
motherapy and recurrence); adequate haematology, he-
patic and renal function; no brain or leptomeningeal
metastases; no signiﬁcant peripheral neuropathy
(P grade 2 according to National Cancer Institute-
Common Toxicity Criteria [NCI-CTC]); no previous or
concurrent malignancies; written informed consent.
Biased-coin randomisation was used to stratify for
institution, liver metastases, prior gastrectomy, weight
loss (>5 or 6 5% over prior 3 months) and the mea-
surability of disease. Biased-coin randomisation is a
dynamic allocation procedure used to minimise the
overall imbalance in prognostic factors by allocating
new treatment on the basis of the characteristics of
previously randomised patients. The allocation is not
deterministic (the ‘‘preferred’’ treatment just has a
higher chance of being allocated, but it is not system-
atically allocated).
2.2. Summary of treatment
Patients were randomised to receive either docetaxel
(75 mg/m2 over 1 h) followed by cisplatin (75 mg/m2
over 1–3 h), both given intravenously on day 1 only,
plus 5-FU (750 mg/m2/day as a continuous infusion over
days 1–5) with cycles repeated every 3 weeks, or cisplatin
(100 mg/m2, on day 1) plus 5-FU (1000 mg/m2/day as a
continuous infusion over days 1–5), with cycles being
repeated every 4 weeks.
A standard supportive regimen of adequate hydra-
tion and as-required anti-emetics was provided.
2.3. Assessments
The primary end-point was time to disease progres-
sion. The major secondary end-point was overall sur-
vival, other secondary end-points being response rate,
time to treatment failure, safety and quality of life.
Tumour response was assessed every 8 weeks, irre-
spective of the treatment schedule. Responses were as-
sessed by the investigator and then reviewed by an
independent external response review committee. All
responses were overseen by the IDMC.
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The ﬁnal analysis of this trial will be conducted on an
intention-to-treat basis. With the recruitment of 230
patients per arm, the study will have 95% power to show
an increase in the median time to progression from 4 to
6 months and an increase in median overall survival
from 8 to 12 months. A total of 325 events and 325
deaths are required, respectively, to show improvements
in time to progression and overall survival, using the
unadjusted log-rank test with two-sided, 5% signiﬁcance
level for statistical analysis.
An interim analysis was built into the study design
when 50% (n ¼ 162) of the time to progression events
required for the interim analysis had occurred. The pre-
speciﬁed boundaries for superiority at this point were
P ¼ 0:0036 for the time to progression and P ¼ 0:0053
for overall survival.3. Results
To date, 463 patients have been randomised to re-
ceive treatment. At the time of the planned interim
analysis, data were available for 223 patients: 111 in the
DCF arm and 112 in the CF arm.
3.1. Demographics
Patient and tumour characteristics were generally
comparable between the two treatment groups (Table
1). Over two-thirds of the patients in each arm were
male, and nearly a quarter of the patients in each arm
were 65 years or older. The majority of patients (63%)
had a good performance status (KPS 90–100%). MoreTable 1
Patient and disease characteristics (interim analysis)
Characteristics DCF (n ¼ 111) CF (n ¼ 112)
Male 69% 71%
Median age, years (range) 52 (26–79) 54 (25–74)
P 65 years 24% 23%
>5% Weight loss in prior
3 months
55% 55%
Karnofsky performance score
90–100 63% 63%
80 37% 35%
Site of primary tumour
Antrum, body 72% 63%
Gastro-oesophageal
junction, fundus
28% 37%
Metastatic cancer 98% 97%
Liver involvement 43% 41%
Measurable disease 83% 88%than half of the patients (55%) had suﬀered a greater
than 5% weight loss in the previous 3 months.
In most patients, the primary tumour site was the
antrum, and this proportion was slightly higher in
the DCF arm than in the CF arm (72% versus 63%). The
vast majority of patients (98% and 97%) had metastatic
disease and over 40% of patients had liver involvement.
Disease was measurable in over 80% of patients.
3.2. Chemotherapy
3.2.1. Chemotherapy delivery
The median duration of treatment was 19 weeks for
the DCF arm and 16 weeks for the CF arm, while the
median dose intensity of cisplatin delivered was similar
in the two arms (23 and 24 mg/m2/week, respectively).
The median dose intensity of 5-FU was slightly higher in
the CF arm (1194 mg/m2/week) than in the DCF arm
(1110 mg/m2/week). The median delivered dose intensity
of docetaxel was 23 mg/m2/week. Dose reduction was
required in 12% of cycles in each arm.
3.2.2. Treatment discontinuation
Compared with the docetaxel arm, nearly twice as
many patients receiving CF discontinued treatment due
to progressive disease (27% versus 47%). Other reasons
for discontinuation in the DCF and CF arms were ad-
verse events (23% and 21%, respectively) and with-
drawal of patient consent (27% and 16%, respectively).
3.3. Eﬃcacy
3.3.1. Response rate
Altogether, 86% of patients in each treatment arm
were evaluable for response. DCF was associated with a
signiﬁcantly higher overall response rate than CF (39%
versus 23%, P ¼ 0:012) (Table 2). Complete responses
were seen in 3% of patients in each arm. Stable disease/
no change was reported in 31% and 35% of patients in
the DCF and CF arms, respectively, with progressive
disease in 18% and 28%.Table 2
Response rate (interim analysis)
Responsea DCF (n ¼ 111) CF (n ¼ 112)
Complete response (CR) 3% 3%
Partial response (PR) 36% 21%
Overall response rate
(CR+PR) [95% CI]
39% [30–49] 23% [16–32]
P value for overall response rate 0.012
No change/stable disease 31% 35%
Disease progression 17% 28%
Not evaluable 14% 14%
CI, conﬁdence intervals.
aAll responses were conﬁrmed independently by external response
review.
Log-rank Test p-value=0.0008
Risk ratio  =1.704
  [95% CI] [1.244,2.335]
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Fig. 1. Time to progression (interim analysis).
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Fig. 2. Probability of progression-free survival at 6 and 9 months of
treatment (interim analysis).
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Of the 162 time to progression events occurring, 77
were in the DCF arm and 85 in the CF arm. The
median time to progression was signiﬁcantly longer in
the DCF arm than in the CF arm (5.2 [95% CI 4.3–
6.8] versus 3.7 [95% CI 3.1–4.8] months, P ¼ 0:0008)
(Fig. 1). The level of signiﬁcance for diﬀerence be-
tween the two treatments was greater than the pre-
speciﬁed boundary for superiority (P ¼ 0:0036). The
hazard ratio (HR) for disease progression with DCF
versus CF was 1.704. The probability of progression-
free survival at 9 months was almost three times
greater in the DCF arm than in the CF arm (31%
versus 11%) (Fig. 2).
3.3.3. Overall survival
The median overall survival was also longer in the
DCF arm compared with the CF arm (10.2 [95% CI 8.5–
12.3] versus 8.5 [95% CI 6.6–9.5] months, P ¼ 0:0064)
(Fig. 3). However, level of signiﬁcance for a diﬀerence
between the treatment arms was lower than the pre-Log
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Fig. 3. Overall survivalspeciﬁed boundary for superiority (P ¼ 0:0053). The
hazard ratio (HR) for risk of death in test versus control
arm was 1.505.-rank test p-value = 0.0064
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Table 3
Grade 3/4 haematological and non-haematological toxicity (interim
analysis)
Toxicity DCF (n ¼ 111)
(%)
CF (n ¼ 112)
(%)
Haematological toxicity
Grade 3/4 neutropenia 84 60
Febrile neutropeniaa 16 6
Neutropenic infectionb 14 7
Grade 3/4 treatment-related non-haematological toxicity
Neurosensory 8 5
Infection 12 6
Anorexia 13 13
Nausea 14 20
Vomiting 15 21
Lethargy 20 19
Diarrhoea 20 8
Stomatitis 23 30
At least 1 treatment-
related non-haematological
grade 3/4 adverse event
68 65
aGrade P 2 fever concomitant with grade 4 neutropenia (without
infection).
bGrade P 2 related infection concomitant with grade 3/4
neutropenia.
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Mortality from any cause within 30 days of the ﬁrst
infusion of treatment was 2% and 3% in DCF and CF
arms, respectively.
3.4.1. Haematological toxicity
Grade 3/4 neutropenia occurred in the majority of
the patients receiving DCF (84%) and more than half of
the CF treated patients (60%) (Table 3). The occurrence
of febrile neutropenia and neutropenic infection was
also higher in the DCF arm.
3.5. Non-haematological toxicity
The incidence of treatment-related grade 3/4 adverse
events was similar in both arms, with at least one
treatment-related event being recorded in 68% and 65%
of DCF and CF arms respectively (Table 3). Grade 3/4
adverse events were mainly related to the gastro-intes-
tinal system and included stomatitis, nausea, vomiting
and diarrhoea. Lethargy and anorexia were also noted.4. Discussion
This planned interim analysis showed that addition of
docetaxel to a regimen of cisplatin/5-FU for the treat-
ment of mainly metastatic gastric carcinoma signiﬁ-
cantly increased the tumour response rate and
prolonged the time to progression, in accordance with
pre-determined signiﬁcance boundaries. At 6 and 9months, progression free survival in the DCF arm was
almost double that in the active control arm. Overall
survival was also signiﬁcantly improved, although the
level of signiﬁcance was lower than that of the pre-de-
termined boundary.
As these results represent an interim analysis, it is
premature to compare them with ﬁnal results from other
phase III trials. However, it is interesting to note that
the median overall survival times in both arms of the
study were higher than those seen in two phase III trials
with 5-FU alone, uracil/tegafur/mitomycin C, ELF,
FAMTX and FUP [5,25]. In addition, the median
overall survival with DCF was longer than that seen in
phase III trials using ECF [26,27].
All cause mortality within 30 days of the ﬁrst treat-
ment infusion was comparable in both arms (2% and
3%). Interestingly, the observed death rate in the CF
arm was only half that reported for the CF regimen in a
phase III trial conducted by the European Organization
for Research and Treatment of Cancer (6%) [5]. All
cause mortality within 30 days of the last infusion was
slightly higher with DCF (12%) than with CF (8%). The
observed mortality rate for CF at this stage of the study
is comparable to that reported in a phase III trial of the
Japan Clinical Oncology Group (7%) [25], even though
lower doses of CF were administered in the Japanese
study.
The haematological toxicity observed with DCF was
predictable and manageable. The type and incidence of
non-haematological toxicities were similar in both arms.
The nausea and vomiting characteristic of the cisplatin
component were not exacerbated by the addition of
docetaxel, the predominant gastrointestinal adverse
events in the DCF arm being stomatitis (23%) and
diarrhoea (20%).
The results from this interim analysis are extremely
encouraging for a disease that generally has a very poor
prognosis, and the ﬁnal analysis should conﬁrm the role
of DCF in metastatic gastric carcinoma. The results
from this trial are particularly promising because of the
robust nature and power of the trial. The V325 protocol
is designed to have 95% power to show 50% increases in
median time to progression and overall survival. As
such, this is the highest-powered trial conducted in
metastatic gastric carcinoma to date. More importantly,
it has 90% power to reveal a signiﬁcant diﬀerence be-
tween treatments in time to progression and overall
survival, assuming these parameters are independent of
each other. An additional factor in the design of this
trial is that the weight loss boundary has been set at the
relatively stringent level of P5% compared with the 10%
level used in the majority of trials. The activity of do-
cetaxel in gastric cancer ensures this drug a role in the
treatment of metastatic disease. It will be necessary to
determine the combinations of docetaxel and other
chemotherapeutic agents which demonstrate optimum
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administering a combination of docetaxel, capecitabine
and cisplatin as ﬁrst-line therapy, and showed it to be
highly active and tolerable (68% response rate among 40
patients) [28]. Docetaxel in combination with irinotecan
has also been shown to be a potential treatment option
[29].
In conclusion, this planned interim analysis showed
that DCF signiﬁcantly improved response rate, time to
progression and overall survival compared with CF and
had acceptable toxicity. The median overall survival
obtained with DCF, at 10 months, is particularly en-
couraging. In view of these ﬁndings, we suggest that
DCF should be considered as ﬁrst-line therapy for pa-
tients with advanced gastric carcinoma. Results from the
ﬁnal analysis are awaited.Appendix
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